ValuEngine lowered shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a research report released on Thursday morning, ValuEngine reports.
Other equities research analysts also recently issued reports about the company. BidaskClub downgraded GW Pharmaceuticals PLC- from a sell rating to a strong sell rating in a research note on Wednesday, July 24th. CIBC raised GW Pharmaceuticals PLC- from a market perform rating to an outperform rating in a research note on Tuesday, May 7th. Cowen reaffirmed a buy rating and set a $200.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Friday, July 26th. Piper Jaffray Companies raised their price target on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an overweight rating in a research note on Tuesday, May 7th. Finally, Morgan Stanley reaffirmed a buy rating on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $203.91.
GW Pharmaceuticals PLC- stock traded down $1.97 during mid-day trading on Thursday, hitting $155.72. The company’s stock had a trading volume of 418,643 shares, compared to its average volume of 320,719. GW Pharmaceuticals PLC- has a 52-week low of $90.14 and a 52-week high of $196.00. The stock’s 50 day moving average is $169.37. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. The firm has a market cap of $4.90 billion, a P/E ratio of -14.75 and a beta of 2.25.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The company had revenue of $39.20 million during the quarter, compared to the consensus estimate of $12.32 million. During the same period last year, the business earned ($3.12) EPS. The business’s quarterly revenue was up 1189.5% on a year-over-year basis. As a group, equities analysts forecast that GW Pharmaceuticals PLC- will post -5.41 earnings per share for the current fiscal year.
In other news, insider Douglas B. Snyder sold 4,968 shares of the stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $14.42, for a total transaction of $71,638.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Justin D. Gover sold 202,224 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $15.24, for a total value of $3,081,893.76. Following the transaction, the chief executive officer now directly owns 743,765 shares in the company, valued at approximately $11,334,978.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,506,720 shares of company stock worth $23,046,711. 3.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE increased its holdings in shares of GW Pharmaceuticals PLC- by 0.6% during the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock valued at $1,969,000 after acquiring an additional 75 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in GW Pharmaceuticals PLC- by 14.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 78 shares during the last quarter. Brandywine Oak Private Wealth LLC grew its holdings in GW Pharmaceuticals PLC- by 6.0% in the 1st quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 81 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in GW Pharmaceuticals PLC- by 4.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 92 shares during the last quarter. Finally, Advisory Services Network LLC grew its holdings in GW Pharmaceuticals PLC- by 23.1% in the 4th quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 96 shares during the last quarter. 78.95% of the stock is currently owned by institutional investors and hedge funds.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More: What is a recession?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.